A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Ferrarotto, Renata
Bell, Diana
Feng, Lei
Li, Kaiyi
Mott, Frank
Blumenschein, George R.
De Sousa, Luana Guimaraes
Altan, Mehmet
Marques-Piubelli, Mario L.
Dal Lago, Eduardo Andreazza
Kaya, Diana
Godoy, Myrna
Kupferman, Michael Elliot
Glisson, Bonnie S.
El-Naggar, Adel K.
Elamin, Yasir Y.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostatist, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[7] Univ Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6019
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).
    Ferrarotto, Renata
    Ho, Alan Loh
    Wirth, Lori J.
    Dekel, Edith
    Walker, Russell W.
    Vergara-Silva, Andrea Leninka
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
    Wong, S. J.
    Karrison, T.
    Hayes, D. N.
    Kies, M. S.
    Cullen, K. J.
    Tanvetyanon, T.
    Argiris, A.
    Takebe, N.
    Lim, D.
    Saba, N. F.
    Worden, F. P.
    Gilbert, J.
    Lenz, H. J.
    Razak, A. R. A.
    Roberts, J. D.
    Vokes, E. E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2016, 27 (02) : 318 - 323
  • [43] Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC)
    Gravalos, C.
    Carrato, A.
    Tobena, M.
    Grande Pulido, E.
    Soler, G.
    Vieitez, J.
    Robles, L.
    Valladares-Ayerbes, M.
    Polo, E.
    Limon, M. L.
    Safont, M. J.
    Lopez, C.
    Garcia Alfonso, P.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma
    Hoff, Camilla O.
    de Sousa, Luana G.
    Bonini, Flavia
    Lago, Eduardo Dal
    Wang, Kaiwen
    Siqueira, Juliana M.
    Mitani, Yoshitsugu
    El-Naggar, Adel K.
    Ferrarotto, Renata
    CANCER MEDICINE, 2025, 14 (05):
  • [45] Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma
    Feeney, Laura
    Jain, Yatin
    Beasley, Matthew
    Donnelly, Oliver
    Kong, Anthony
    Moleron, Rafael
    Nallathambi, Chandran
    Rolles, Martin
    Sanghera, Paul
    Tin, Aung
    Ulahannan, Danny
    Walter, Harriet S.
    Webster, Richard
    Metcalf, Robert
    CANCERS, 2021, 13 (17)
  • [46] A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)
    Agulnik, Mark
    Cohen, Ezra E.
    Cohen, Roger B.
    Chen, Eric X.
    Hotte, Sebastien J.
    Winquist, Eric
    Laurie, Scott
    Hayes, D. N.
    Dancey, Janet E.
    Siu, Lillian L.
    ANNALS OF ONCOLOGY, 2006, 17 : 179 - 179
  • [47] Phase 2 Study of Apatinib, A Novel VEGFR Inhibitor in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Preliminary Results
    Dou, S.
    Zhang, L.
    Li, R.
    Zhu, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1378 - 1379
  • [48] Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract
    Licitra, L.
    Pistillo, P.
    Locati, L. D.
    ANNALS OF ONCOLOGY, 2015, 26 : 70 - 70
  • [49] Treatment outcome of 265 patients with sinonasal adenoid cystic carcinoma (ACC)
    Akbaba, S.
    Ahmed, D.
    Mock, A.
    Lang, K.
    Held, T.
    Herfarth, K.
    Rieken, S.
    Plinkert, P.
    Debus, J.
    Adeberg, S.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S196 - S197
  • [50] A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Muzaffar, Jameel
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Yun, Tak
    Sari, Suha
    Conlan, Maureen G.
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345